-
公开(公告)号：EP2718318B1
公开(公告)日：2018-07-25
申请号：EP12797363.4
申请日：2012-06-07
发明人： JUNG, Sung Youb , JANG, Myung Hyun , SHEN, Ling Ai , PARK, Young Kyung , PARK, Young Jin , KWON, Se Chang
IPC分类号： C07K14/605 , A61K38/26 , A61P3/04
CPC分类号： C07K14/605 , A61K38/00 , A61K38/177 , A61K38/22 , A61K38/26 , A61K45/06 , C07K14/575 , C07K14/705
摘要： The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
-
2.发明公开COMPOSITION FOR TREATING DIABETES COMPRISING LONG-ACTING INSULIN CONJUGATE AND LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE 审中-公开组合物对于糖尿病的WITH A LANGWIRKENDEM胰岛素缀合于治疗和长效促胰岛素肽缀合物
公开(公告)号：EP2717918A2
公开(公告)日：2014-04-16
申请号：EP12792243.3
申请日：2012-06-01
发明人： WOO, Young Eun , JANG, Myung Hyun , PARK, Young Jin , PARK, Young Kyung , LIM, Chang Ki , KWON, Se Chang
CPC分类号： A61K47/48415 , A61K38/26 , A61K38/28 , A61K47/68 , A61K47/6811 , A61K47/6883
摘要： The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved
in-vivo duration of efficacy and stability.-
3.发明公开
公开(公告)号：EP3878859A1
公开(公告)日：2021-09-15
申请号：EP21161174.4
申请日：2012-06-07
发明人： JUNG, Sung Youb , JANG, Myung Hyun , SHEN, Ling Ai , PARK, Young Kyung , PARK, Young Jin , KWON, Se Chang
IPC分类号： C07K14/605 , A61K38/26 , A61P3/04
摘要： The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
-
4.发明授权A PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE 有权药物组合物，疾病治疗与肥胖相关的WITH A促胰岛素肽缀合物
公开(公告)号：EP2227243B1
公开(公告)日：2014-08-13
申请号：EP08855148.6
申请日：2008-11-28
发明人： SONG, Dae Hae , KIM, Min Young , PARK, Young Jin , KANG, Eun Hee , JUNG, Sung Youb , KWON, Se Chang , LEE, Gwan Sun
IPC分类号： A61K38/16 , A61P3/04 , A61K39/395 , A61K38/26 , A61K38/22 , A61K47/48 , A61K31/365
CPC分类号： A61K38/26 , A61K31/137 , A61K38/22 , A61K38/2207 , A61K47/6811 , A61K47/6835 , A61K47/6889 , A61K2300/00
-
公开(公告)号：EP2552474A2
公开(公告)日：2013-02-06
申请号：EP11763093.9
申请日：2011-04-04
发明人： SONG, Dae Hae , SHIN, Jae Hee , PARK, Young Jin , IM, Dae Seong , BAE, Sung Min , KWON, Se Chang
CPC分类号： A61K38/28 , A61K47/68 , A61K47/6883 , C07K14/62 , C07K2319/30
摘要： The present invention relates to an insulin conjugate having improved in vivo duration and stability, which is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.
-
公开(公告)号：EP2552474B1
公开(公告)日：2017-02-22
申请号：EP11763093.9
申请日：2011-04-04
发明人： SONG, Dae Hae , SHIN, Jae Hee , PARK, Young Jin , IM, Dae Seong , BAE, Sung Min , KWON, Se Chang
CPC分类号： A61K38/28 , A61K47/68 , A61K47/6883 , C07K14/62 , C07K2319/30
-
7.发明公开NOVEL OXYNTOMODULIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY COMPRISING THE SAME 有权新OXYNTOMODULINDERIVATE和药物组合物，肥胖的顺序处理
公开(公告)号：EP2718318A2
公开(公告)日：2014-04-16
申请号：EP12797363.4
申请日：2012-06-07
发明人： JUNG, Sung Youb , JANG, Myung Hyun , SHEN, Ling Ai , PARK, Young Kyung , PARK, Young Jin , KWON, Se Chang
IPC分类号： C07K14/605 , A61K38/26 , A61P3/04
CPC分类号： C07K14/605 , A61K38/00 , A61K38/177 , A61K38/22 , A61K38/26 , A61K45/06 , C07K14/575 , C07K14/705
摘要： The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
摘要翻译： 本发明涉及到示出了上样肽-1受体和比天然泌酸调节肽胰高血糖素受体，以及用于预防或治疗肥胖症，包括肽作为活性在成分的组合物胰高血糖素更优异的活性的新的肽。 与天然泌酸调节肽，本发明的新的肽减少食物摄入，胃排空禁止显示，并且促进脂肪分解具有降低的副作用，并且因此显示出优异的受体激活作用。 因此，它可广泛应用于肥胖的治疗安全和疗效使用。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.01 秒)
